IMV Inc trades with the ticker IMV on the TSX and is in the Biotechnology industry.
Overview
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Looking to invest in IMV Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.
Table of Contents
show
IMV.TO Stock Price and Key Stats
ETF Key Stats
Exchange: TSX
Market Cap : $13.117MM
PE Ratio:
Price: 4815.5 (Updated: 3/12/2024 0:47:16)
IMV Inc (IMV) vs Competitors in Biotechnology
Lets see how IMV.TO stacks up against others in the Biotechnology asset management industry. We have identified its main peers as:Aeterna Zentaris Inc, Aptose Biosciences Inc, BELLUS Health Inc, Fennec Pharmaceuticals Inc, Intellipharmaceutics International Inc
.Biotechnology Industry Comparisons
| Company | Market Cap ($MM) | P/E Ratio | EV/EBITDA | Dividend Yield |
|---|---|---|---|---|
| Aeterna Zentaris Inc (AEZS) | $12.674 | N/A | 1.709 | N/A% |
| Aptose Biosciences Inc (APS) | $33.927 | N/A | -0.231 | N/A% |
| BELLUS Health Inc (BLU) | $2,470.298 | N/A | -16.428 | 0.0% |
| Fennec Pharmaceuticals Inc (FRX) | $352.565 | N/A | -21.793 | N/A% |
| IMV Inc (IMV) | $13.117 | N/A | -0.843 | 0.0% |
EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield
Comparisons within Biotechnology
- IMV Inc (IMV) vs Aeterna Zentaris Inc (AEZS)
- IMV has higher EPS (-6.11 vs -6.47). IMV provides dividends, while AEZS does not. AEZS and IMV both have P/E’s under 0.
- IMV Inc (IMV) vs Aptose Biosciences Inc (APS)
- IMV has higher EPS (-6.11 vs -10.45). IMV provides dividends, while APS does not. APS and IMV both have P/E’s under 0.
- IMV Inc (IMV) vs BELLUS Health Inc (BLU)
- BLU has higher EPS (-0.96 vs -6.11). BLU has higher dividend yield (0.0% vs 0.0%). BLU and IMV both have P/E’s under 0.
- IMV Inc (IMV) vs Fennec Pharmaceuticals Inc (FRX)
- FRX has higher EPS (-1.01 vs -6.11). IMV provides dividends, while FRX does not. FRX and IMV both have P/E’s under 0.
- IMV Inc (IMV) vs Intellipharmaceutics International Inc (IPCI)
- IPCI has higher EPS (-0.12 vs -6.11). IMV provides dividends, while IPCI does not. IPCI and IMV both have P/E’s under 0.
Our Recommendation: Review
May not stand out on key metrics or lacks sufficient data for a strong recommendation.
How to Buy IMV stock on the TSX
You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:| Image | Product Title | Features | Price |
|---|---|---|---|
Editor's Choice  |
| Get $25 Signup Bonus | |
Reliable Pick  |
| Get $50 Free Stock Trades |
